Insider trade

CFO sold ~$278K of BMY shares in the open market

Traded Apr 1, 2026 · Filed Apr 2, 2026

~$278K
Reported value · 4,481 sh @ $62.05: 159K
Holds after · shares reported: -0.4%
stock since the trade · S&P 500 +16.6%, $61.73 → $61.46 on Oct 1

Why it stands out

The money chief of Bristol Myers Squibb sold $278K of Bristol Myers Squibb shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 1, 2026
Reporting period: Not applicable
Filed with the SEC: Apr 2, 2026

CFO$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$278,046

Shares × reported transaction price

Timing vs results

55 days after results of Feb 5, 2026, 29 days before results of Apr 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $61.73 on Apr 1, 2026, within 2% of its 52-week high, after a 3% rise over the previous 30 trading days

52-week range $42.60 (Oct 29, 2025) to $62.37 (Feb 27, 2026), 97% of the way up, from 251 adjusted closes. 30 trading days earlier: $59.73 on Feb 18, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Opdivo on Mar 20, 2026, 12 days before this trade.

New use approved (efficacy supplement). Active ingredient: Nivolumab. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-2.1%	+4.1%	-6.3%
30 days	-4.6%	+11.4%	-16.0%
90 days	-4.4%	+14.0%	-18.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001451604-26-000004
Filed / recorded: Apr 2, 2026, 8:29 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: BRISTOL MYERS SQUIBB CO
Issuer CIK: 14272
Ticker: BMY
Reporting person: David V Elkins
Relationship: Officer
Officer title: EVP, Chief Financial Officer
Security: Common Stock, $0.10 par value
Table: Non-derivative (Table I)
Transaction date: Apr 1, 2026
Transaction code: S
Shares / units: 4,481
Price per share: $62.05
Acquired / disposed: Disposed (D)
Shares owned after: 159,248
Ownership form: Direct
Amendment: No

Footnotes from the filing

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025.
The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

Around the same time

6mo ago

3,307Shares

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

6mo ago

1,692Shares · @ $61.73

Routine share withholding; mechanical by default.

Why it stands out Official record

6mo ago

3,307Derivative units

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record